Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-3 of 3
Keywords: Pirarubicin
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1993) 16 (6): 450–453.
Published Online: 08 May 2009
...M. Raderer; D. Depisch; K. Haider; W. Kwasny; M. Djavanmard; W. Scheithauer Background : Because MDRl RNA is frequently encountered in advanced breast cancer, we have initiated a phase I/II study with pirarubicin in combination with the multidrug resistance modifier quinidine. Patients and Methods...
Journal Articles
Subject Area:
Oncology
U.R. Kleeberg, L. Reichel, H.-E. Wander, J.-H. Beyer, U. Essers, H.H. Fiebig, E. Salewski, B. Greifenberg, L. Edler
Journal:
Onkologie
Onkologie (1990) 13 (3): 175–179.
Published Online: 28 April 2009
...U.R. Kleeberg; L. Reichel; H.-E. Wander; J.-H. Beyer; U. Essers; H.H. Fiebig; E. Salewski; B. Greifenberg; L. Edler Pirarubicin is a more lipophilic derivative of doxorubicin, with a higher uptake rate of cells, lower cardiotoxicity and better antitumor efficacy in preclinical models. Thirty-four...
Journal Articles
Subject Area:
Oncology
Journal:
Onkologie
Onkologie (1990) 13 (3): 180–184.
Published Online: 28 April 2009
...P. Drings; I.U. Günther; U. Gatzemeier; W. Berdel; M. Stahl; E. Salewski; L. Edler Forty-seven patients with advanced non-small cell lung cancer (NSCLC) were treated in a multicentre phase II study with pirarubicin (THP), 4’-O-tetrahydropyranyl-doxorubicin using a dosage of 70mg/ m2 every 3 weeks...
